Literature DB >> 1347936

Pharmacologic treatment of attention deficit hyperactivity disorder.

L L Greenhill1.   

Abstract

This article describes the role of psychostimulant medication in the treatment of attention deficit hyperactivity disorder. Included are the drugs' putative mechanisms of action, pharmacology, toxicology, indications for their use, short-term and long-term actions, adverse effects, specific dosing regimens, therapeutic monitoring techniques, alternative medications, and drug interactions.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1347936

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN： 0193-953X


  15 in total

1.  Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.

Authors:  Francesco Napolitano; Alessandra Bonito-Oliva; Mauro Federici; Manolo Carta; Francesco Errico; Salvatore Magara; Giuseppina Martella; Robert Nisticò; Diego Centonze; Antonio Pisani; Howard H Gu; Nicola B Mercuri; Alessandro Usiello
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 2.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

3.  The development of selective attention in children with attention deficit hyperactivity disorder.

Authors:  D A Brodeur; M Pond
Journal:  J Abnorm Child Psychol       Date:  2001-06

4.  Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers.

Authors:  Akwete Adjei; Robert J Kupper; Nathan S Teuscher; Sharon Wigal; Floyd Sallee; Ann Childress; Scott H Kollins; Laurence Greenhill
Journal:  Clin Drug Investig       Date:  2014-11       Impact factor: 2.859

5.  Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study.

Authors:  M R Lyon; J C Cline; J Totosy de Zepetnek; J J Shan; P Pang; C Benishin
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 6.  The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD).

Authors:  B H Smith; D A Waschbusch; M T Willoughby; S Evans
Journal:  Clin Child Fam Psychol Rev       Date:  2000-12

Review 7.  Effective treatment for mental disorders in children and adolescents.

Authors:  B J Burns; K Hoagwood; P J Mrazek
Journal:  Clin Child Fam Psychol Rev       Date:  1999-12

8.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Association of attention-deficit disorder and the dopamine transporter gene.

Authors:  E H Cook; M A Stein; M D Krasowski; N J Cox; D M Olkon; J E Kieffer; B L Leventhal
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

10.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.